50/500 mg
Trade Name
Sitavia-MET
Film-coated tablet
Request Type
Registration
Drug Type
Generic(Multisource) Drug
Approval Date
SFDA Approved Use
For adult patients with type 2 diabetes mellitus:
Sitavia-MET is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately
controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination
of sitagliptin and metformin.
Sitavia-MET is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to
diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a
sulphonylurea.
Sitavia-MET is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma
(PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled
on their maximal tolerated dose of metformin and a PPARγ agonist.
Sitavia-MET is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and
exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide
adequate glycaemic control.
Sitavia-MET is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately
controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination
of sitagliptin and metformin.
Sitavia-MET is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to
diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a
sulphonylurea.
Sitavia-MET is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma
(PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled
on their maximal tolerated dose of metformin and a PPARγ agonist.
Sitavia-MET is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and
exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide
adequate glycaemic control.